Stride Raises £4.6m to Bring Personalised Preventative Healthcare to More People

What if people could understand potential health risks before they become bigger problems? UK healthtech startup Stride is building its business around that idea, and a new £4.6 million seed round will help it take the next step.

Founded in May 2024 by Andrew Steele, an Olympic medallist and co-founder of genetic testing business DNAfit, Stride combines DNA, blood and gut health testing with personalised insights. Its membership service aims to help people make better-informed decisions about their health by looking at different types of biological data together rather than treating each test as an isolated result.

The round includes investment from Arāya Ventures, Better Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Innovate UK and an investor from the a16z Scout Fund, alongside individual angel investors. It is Stride’s first external funding round.

Where will the £4.6m go?

Stride plans to use the investment to develop its platform, broaden its testing options and expand beyond the UK.

One priority is a multi-source biological age test, which the company is developing to combine different types of health data. It has also secured Innovate UK support for research into measuring biological age and developing an AI-powered health copilot.

The proposed copilot is intended to bring together information such as laboratory results, wearable data and health records to provide more personalised insights. The aim is to make complex health information easier to understand and turn into practical next steps.

International expansion is another major focus. Stride plans to launch its StrideOne membership outside the UK before the end of 2026, with the United States among its target markets.

The company reports that it has already served more than 16,000 customers and retained 85% of StrideOne members over their first 13 months. These are company-reported figures, but they offer an indication of the traction behind its next growth phase.

Why this funding matters

Preventative healthcare and longevity services are attracting interest as consumers look for more personalised ways to manage their wellbeing. However, turning that interest into a sustainable business requires more than collecting data. Companies need to earn customer trust, explain results responsibly and give people a clear reason to keep paying for the service.

For Stride, the challenge is making sophisticated testing and personalised guidance accessible beyond a niche wellness audience. Expanding internationally will also require the company to understand different customer expectations and the regulatory requirements of each market.

The funding gives Stride more room to develop its technology and test whether its membership model can grow across borders. Its next stage will depend on delivering useful insights consistently, retaining customers and demonstrating the value of ongoing preventative health support.

For founders, Stride’s journey is a reminder that raising capital is only one milestone. The harder work is using that money to build a product customers return to and a business that can scale sustainably.

💬 Join Our Discord Community

Don't build your business alone. Join thousands of founders, entrepreneurs, and startup professionals sharing funding opportunities, industry news, events, partnerships, and practical advice every day.

Would you pay for a membership that combines health testing with personalised guidance, or do you think preventative healthcare should remain primarily within traditional healthcare services?